The Long Read / Switzerland: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive…
Top Stories
China / Top 10 Pharma Companies 2020
The Top 10 Chinese pharma companies for 2020 ranked by overall revenues. Taken from Fortune magazine's 2020 list of the 500 biggest companies in China, this up-to-date list shows Shanghai…
Saudi Arabia / SFDA CEO Sets Out Strategic Priorities
In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug…
Turkey / The Impact Of Brexit On CE Certificates Issued By UK Notified Bodies
The shockwaves from the UK’s exit from the European Union have resounded across the continent, including in…
Switzerland / Ichnos CEO on Glenmark Legacy, Biotech Transformation & CAR-T Complementarity
After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer…
LatAm / COVAX Rollout in Colombia; União Quimica to Manufacture Sputnik Vaccine in Brazil; Mexico Cannabis Update
The latest LatAm pharma news, including COVID-19 vaccine rollouts in Colombia, Brazil, and Mexico as well as legal…
China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
In Conversation
Ashish D Pal – Managing Director, MSD Singapore, Malaysia & Brunei Cluster; President, Singapore Association of Pharmaceutical Industries (SAPI); Vice-President, Pharmaceutical Association of Malaysia (PhAMA)
MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more resilient, agile, and digitally-focused affiliate; and why increased levels of public-private collaboration in the region are vital to building a sustainable and enabling environment for access to innovative medicines and…
Latest Reports
Focus on Europe
Can Europe’s Beating Cancer Plan Make it an Innovation…
The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating…
Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that…
After Brexit: Focus on the New Pharmaceutical Strategy for…
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler…
Read more: Europe >>
Focus on China
Boehringer Ingelheim’s Stroke Rehab Centre Success…
In March 2018, German pharma player Boehringer Ingelheim (BI)'s Consanas…
Top 10 Chinese Pharma Companies 2020
The Top 10 Chinese pharma companies for 2020 ranked by overall revenues. Taken…
New Drug Approvals in China 2020
The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals…
China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics…
The latest from Chinese pharma, including a new deal between AstraZeneca and…
Read more: China >>
Focus on USA
USA: 2 Things the Biden Administration can do Now to Lower…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can…
NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading…
Novavax: From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor…
Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and…
Read more: USA >>
Focus on Vaccines
Italy: Stevanato’s $5 bn valuation; Zolgensma Approval;…
The latest from Italian pharma, including the foreign minister’s plea for…
Novavax: From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor…
The COVID-19 Vaccine Rush: Nationalism, Access & IP…
The global rush to secure access to COVID-19 vaccines has led to accusations…
German Pharma: Highest Honours for BioNTech Founders;…
A roundup of some of the most important recent news from German pharma,…
Read more: Vaccines >>
Focus on Switzerland
Ichnos CEO on Glenmark Legacy, Biotech Transformation &…
After an illustrious career in oncology R&D, contributing greatly to the…
Swiss Pharma: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland…
ISREC’s Susan Gasser: A “Hard-Nosed” Approach to…
After 15 years as director at the Friedrich Miescher Institute for Biomedical…
Swissmedic New Drug Approvals 2020
Regarded as one of the world’s leading regulatory bodies, Swissmedic stands…
Read more: Switzerland >>
Focus on MEA
5 Things to Know about Saudi Arabian Pharma
A rundown of five things to know about the USD 8.2 billion Saudi pharma market,…
5 Saudi Arabian Pharma Companies to Know
Following on from our list of the overall top 10 companies in the Saudi Arabian…
MEA: Iran looks to Cuba for COVID-19 Vaccine; Israel Leads…
The latest COVID-19 vaccine news from the Middle East & Africa (MEA) region,…
Saudi Arabia: SFDA CEO Sets Out Strategic Priorities
In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey,…
Read more: MEA >>
Focus on Singapore
Medtech’s Post-COVID Paradigm in APAC
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech…
Singapore Pharma Industry Snapshot 2020
Singapore is home to a wide range of biopharmaceutical company headquarters,…
Southeast Asia: Singapore Pharma Production Surge;…
The latest from Southeast Asian pharma, including soaring output in Singapore,…
APAC: Prestige & HH&L IPO News; Cold Chain Vaccine…
The latest pharma news from the Asia-Pacific region, including upcoming IPOs for…